PTC cuts 25% of its work­force to save mon­ey amid big com­pa­ny re­vamp 

Rare dis­ease com­pa­ny PTC Ther­a­peu­tics is lay­ing off an ad­di­tion­al 25% of its work­force as it dis­con­tin­ues gene ther­a­py ef­forts and works on sal­vaging its Duchenne mus­cu­lar dy­s­tro­phy drug Translar­na in Eu­rope.

The ma­jor­i­ty of af­fect­ed em­ploy­ees work in ear­ly-stage re­search and PTC’s gene ther­a­py man­u­fac­tur­ing fa­cil­i­ty lo­cat­ed in Hopewell, NJ. Em­ploy­ees work­ing in sales and gen­er­al and ad­min­is­tra­tive func­tions are al­so af­fect­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER